Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data

Stock Track

04/27

AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.

The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.

The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1125463972"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125463972\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125463972?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 13:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125463972","market":"nz","top_or_hot":-1,"title":"Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data","media":"Stock Track","content":"<p>AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.</p><p>The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-27 13:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.</p><p>The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1125463972","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125463972","pubTimestamp":1777266211,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by continued positive investor...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|康方生物盘中大涨5.24%胰腺癌II期试验数据积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}